Companies such as Syrah Resources and ImpediMed have a significantly positive future outlook on the basis of their profitability and returns. Investors seeking to enhance their portfolio should consider these financially stable, high-growth stocks. Analysing the most recent financial data, I’ve created a list of companies that compare favourably in all criteria, making them potentially good additions to your portfolio.

Syrah Resources Limited (ASX:SYR)

Syrah Resources Limited, together with its subsidiaries, engages in the exploration, evaluation, and development of mineral properties in Mozambique. The company provides employment to 374 people and with the company’s market cap sitting at AUD A$1.17B, it falls under the small-cap group.

Extreme optimism for SYR, as market analysts projected an outstanding earnings growth rate of 50.19% for the stock, supported by an equally strong sales. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. We see this bottom-line expansion directly benefiting shareholders, with expected positive return on equity of 15.45%. SYR’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Could this stock be your next pick? Other fundamental factors you should also consider can be found here.

ImpediMed Limited (ASX:IPD)

ImpediMed Limited, together with its subsidiaries, engages in the development, manufacture, and sale of bioimpedance devices and consumables in Australia, North America, Europe, and internationally. Started in 1999, and currently run by Richard Carreon, the company employs 76 people and with the company’s market capitalisation at AUD A$302.47M, we can put it in the small-cap group.

IPD’s forecasted bottom line growth is an exceptional 66.54%, driven by underlying sales, which is expected to more than double, over the next few years. It appears that IPD’s profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 36.58%. IPD ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Should you add IPD to your portfolio? Take a look at its other fundamentals here.

Medibio Limited (ASX:MEB)

Medibio Limited, a medical technology company, engages in the research, development, and commercialization of medical diagnostic technology for mental health based on circadian heart rate data in Australia. The company was established in 1998 and with the company’s market cap sitting at AUD A$56.11M, it falls under the small-cap stocks category.

An outstanding 94.22% earnings growth is forecasted for MEB, driven by strong underlying sales growth over the next few years. It appears that MEB’s profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 42.90%. MEB’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Could this stock be your next pick? Check out its fundamental factors here.

For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.